valsartan, amlodipine, HCTZ + Losartan, HCTZ followed by valsartan, amlodipine, HCTZ
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Stage 2 Systolic Hypertension
Conditions
Stage 2 Systolic Hypertension
Trial Timeline
Jul 1, 2009 → Jan 1, 2010
NCT ID
NCT00931710About valsartan, amlodipine, HCTZ + Losartan, HCTZ followed by valsartan, amlodipine, HCTZ
valsartan, amlodipine, HCTZ + Losartan, HCTZ followed by valsartan, amlodipine, HCTZ is a approved stage product being developed by Novartis for Stage 2 Systolic Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT00931710. Target conditions include Stage 2 Systolic Hypertension.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00931710 | Approved | Completed |
Competing Products
20 competing products in Stage 2 Systolic Hypertension